ReviewPediatric endocrinology, diabetes, and metabolism2025
Chemotherapy-induced osteoporosis in pediatric oncology: pathophysiology and treatment.
Review in Pediatric endocrinology, diabetes, and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile osteoporosis is an increasingly recognized long-term complication in pediatric oncology. While advances in cancer therapy have improved survival, aggressive treatment protocols - chemotherapy, glucocorticoids, radiotherapy, surgery - often disrupt skeletal development during key phases of bone accrual. This review outlines the multifactorial pathophysiology of therapy-induced bone loss in children with cancer. The imbalance between bone formation and resorption is driven by inflammation, oxidative stress, hormonal deficits and direct drug toxicity. Agents such as methotrexate and glucocorticoids impair osteoblast function and enhance osteoclastogenesis. Endocrinopathies - particularly hypogonadism and growth hormone deficiency - further compromise peak bone mass acquisition. Compounding these effects are post-treatment nutritional deficits, physical inactivity, and psychological fatigue. Many survivors consume high-fat, low-nutrient diets and avoid exercise, worsening musculoskeletal health. These behaviors often stem from insufficient rehabilitation support and emotional exhaustion, perpetuating deconditioning and elevating fracture risk. Genetic factors are also implicated. Mutations in low-density lipoprotein receptor-related protein 5 (LRP5) and estrogen receptor 1 (ESR1) are associated with reduced bone mineral density in pediatric patients. Diagnosis is complicated by evolving pediatric criteria for bone density and growth-related variability in biomarkers. Nonetheless, early identification and continuous monitoring are essential. Interventions such as individualized physical activity programs, nutritional repletion, endocrine evaluation, and bisphosphonate therapy may counteract skeletal decline. In conclusion, secondary osteoporosis in pediatric cancer survivors reflects a convergence of oncologic, metabolic, behavioral, and genetic factors. Effective management requires early, multidisciplinary strategies targeting modifiable risks and predictive markers to preserve bone integrity and improve long-term quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.